Literature DB >> 1555983

Clinical stage I endometrial cancer: prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system.

P W Grigsby1, C A Perez, A Kuten, J R Simpson, D M Garcia, H M Camel, M S Kao, A E Galakatos.   

Abstract

A retrospective analysis is reported in 858 patients with clinical Stage I carcinoma of the endometrium treated definitively with combined irradiation and total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) from January 1960 through December 1986. Most patients received a preoperative intracavitary insertion (3500-4000 mgh to the uterus and a 6500 cGy surface dose to the upper vagina) followed by a TAH-BSO within 1-2 weeks. Some patients received postoperative external beam irradiation (2000 cGy whole pelvis and an additional 3000 cGy to the parametria, with a midline stepwedge) when factors such as deep myometrial invasion were present. Occasionally patients were treated with a preoperative intracavitary insertion and preoperative external beam irradiation (2000 cGy whole pelvis). The 5-year progression-free survivals by FIGO (1988) surgical stage were 93% for IA, 90% for IB, and 91% for Stage IC. An analysis of multiple variables was performed to ascertain their prognostic significance. Factors that significantly affected the 5-year progression-free survivals by univariate analysis were grade (grade 1 = 95%, grade 2 = 88%, grade 3 = 73%; p less than 0.0001), histology (adenoacanthoma = 96%, clear cell = 89%, adenocarcinoma = 89%, papillary = 81%, adenosquamous = 80%; p = 0.04), lower uterine segment involvement (uninvolved = 89%, involved = 73%; p = 0.006), depth of myometrial invasion (no residual tumor = 91%, limited to the endometrium = 96%, less than 1/3 myometrial penetration = 92%, 1/3 - 2/3 = 100%, greater than 2/3 = 50%; p = 0.02), peritoneal cytology (negative = 92%, positive = 56%, p less than 0.0001), uterine serosal involvement (uninvolved = 89%, involved = 55%; p less than 0.0001), vascular space invasion (absent = 89%, present = 75%; p = 0.001), and the presence of extrauterine disease (absent = 90%, present = 64%; p less than 0.0001). A multivariate analysis of these prognostic variables showed that histological grade (p = 0.001), peritoneal cytology (p = 0.004), and uterine serosal involvement were prognostic for local failure and that peritoneal cytology (p less than 0.001), grade (p = 0.001), age (p = 0.002), and extrauterine disease (p = 0.02) were prognostic for the development of distant metastasis.

Entities:  

Mesh:

Year:  1992        PMID: 1555983     DOI: 10.1016/0360-3016(92)90786-h

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

1.  Appendiceal metastasis 10 years following 'curative' resection for low-grade primary endometrial carcinoma.

Authors:  Alfred Bentsi Addison; Katy Miller; Dalia Hammouch; Naseem Waraich; Phillip Kaye; Rakesh Kapur; William Tennant
Journal:  BMJ Case Rep       Date:  2012-03-20

2.  Two cases of successful pregnancies after hysteroscopic removal of endometrioid adenocarcinoma grade I, stage IA, in young women with Lynch syndrome.

Authors:  Ingrid Marton; Hrvojka Soljacic Vranes; Vladimir Sparac; Igor Maricic; Krunoslav Kuna; Miroslav Kopjar
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-01-06

3.  Is adjuvant radiotherapy necessary for FIGO stage 1a grade 2 endometrial endometrioid adenocarcinoma?

Authors:  Abdurrahman Hamdi İnan; Gülçin Şahin Ersoy; Yusuf Yıldırım; Tutku Gürbüz; Ayşe Gül Kebapçılar; Merih Hanhan
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-07-14

4.  Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma.

Authors:  Hakan Karagol; Pinar Saip; Kazim Uygun; Seden Kucucuk; Adnan Aydiner; Erkan Topuz
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

5.  Improving locoregional outcome in high-intermediate-risk and high-risk stage I endometrial cancer with surgical staging followed by brachytherapy.

Authors:  Candan Demiroz Abakay; Sonay Arslan; Meral Kurt; Sibel Cetintas
Journal:  Radiat Oncol J       Date:  2022-05-25

6.  Patterns of failure after postoperative radiation therapy for endometrial carcinoma.

Authors:  Suzy Kim; Hong-Gyun Wu; Hyo-Pyo Lee; Soon-Beom Kang; Yong-Sang Song; Noh-Hyun Park; Sung Whan Ha
Journal:  Cancer Res Treat       Date:  2006-06-30       Impact factor: 4.679

7.  Adjuvant therapy in high-risk early endometrial carcinoma: a retrospective analysis of 46 cases.

Authors:  Jin Hwi Kim; Sung Jong Lee; Jeong Hoon Bae; Sung Ha Lee; Seog Nyeon Bae; Sung Eun Namkoong; Jong Sup Park
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

Review 8.  Typical and atypical metastatic sites of recurrent endometrial carcinoma.

Authors:  Vikram Kurra; Katherine M Krajewski; Jyothi Jagannathan; Angela Giardino; Suzanne Berlin; Nikhil Ramaiya
Journal:  Cancer Imaging       Date:  2013-03-26       Impact factor: 3.909

9.  High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome.

Authors:  Gustavo A Viani; Barbara F Patia; Antonio C Pellizzon; Marcel D De Melo; Paulo E Novaes; Ricardo C Fogaroli; Maria A Conte; Joao V Salvajoli
Journal:  Radiat Oncol       Date:  2006-08-03       Impact factor: 3.481

10.  Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer.

Authors:  K Ino; N Yoshida; H Kajiyama; K Shibata; E Yamamoto; K Kidokoro; N Takahashi; M Terauchi; A Nawa; S Nomura; T Nagasaka; O Takikawa; F Kikkawa
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.